EP Patent

EP2710003A1 — Fused bicyclic kinase inhibitors

Assigned to OSI Pharmaceuticals LLC · Expires 2014-03-26 · 12y expired

What this patent protects

Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Ab…

USPTO Abstract

Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention.

Drugs covered by this patent

Patent Metadata

Patent number
EP2710003A1
Jurisdiction
EP
Classification
—
Expires
2014-03-26
Drug substance claim
No
Drug product claim
No
Assignee
OSI Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.